News

OpGen Group Company Ares Genetics Nominated for Austrian Innovation Award for AI-powered Molecular Antibiotic Susceptibility Test

VIENNA, Austria, and GAITHERSBURG, Md., Sept. 08, 2020 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”), announced today that its subsidiary Ares Genetics GmbH (Vienna, Austria; “Ares Genetics”) has been nominated for the 40th Austrian Innovation Award (Ref. 1). Ares Genetics has been selected by an expert jury as one of six finalists for its…

Read More

OpGen Announces CE-IVD Marking and Commercial Launch in Europe of its Own Developed Molecular Diagnostic SARS-CoV-2 Kit with PULB for Detection of the Virus Causing COVID-19

GAITHERSBURG, Md., and HOLZGERLINGEN, Germany, Aug. 20, 2020 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that its subsidiary Curetis GmbH has obtained the CE mark certification in the European Union for its own SARS-CoV-2 Kit with PULB for the detection of SARS-CoV-2, the virus…

Read More

New Study Published in the Journal of the National Cancer Institute Concludes that Epi proColon® is the Test of Choice for the Millions of Individuals Not Willing to Participate in FIT or Colonoscopy Screening

BERLIN and SAN DIEGO, Aug. 10, 2020 (GLOBE NEWSWIRE) — Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) announces that a study published by the NCI-sponsored cancer intervention and surveillance modeling network (CISNET) in the Journal of the National Cancer Institute reported that by comparing the incremental cost-effectiveness of CTC, PillCam, mtSDNA (Cologuard)…

Read More

OpGen Group Company Ares Genetics Demonstrates Feasibility of CLIA-compliant Next Generation Sequencing Workflow for Identification of Bacterial Pathogens and Antibiotic Resistance Markers

VIENNA, Austria, and GAITHERSBURG, Md., Aug. 11, 2020 (GLOBE NEWSWIRE) — Ares Genetics GmbH (Vienna, Austria; “Ares Genetics”), a subsidiary of OpGen, Inc. (Nasdaq: OPGN, “OpGen”), announced today the publication of a peer-reviewed study that demonstrates the feasibility of a highly accurate and reproducible sample-to-insight workflow for various clinical microbiology assays including the molecular identification…

Read More

OpGen Co-Markets COVID-19 Antibody Test Kit

GAITHERSBURG, Md., Aug. 09, 2020 (GLOBE NEWSWIRE) — As disclosed in OpGen, Inc.’s (NASDAQ: OPGN) (“OpGen” or “the Company”) July 13, 2020 press release, we have commenced marketing and promotion, on a non-exclusive basis, of certain products offered by Menarini Silicon Biosystems (MSB) to infectious disease healthcare providers and researchers. As part of the co-promotion…

Read More

Menarini Silicon Biosystems Partners with OpGen to Broaden Distribution of CELLSEARCH Platform in North America

BOLOGNA, Italy and HUNTINGDON VALLEY, Pa. and GAITHERSBURG, Md., July 13, 2020 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that it has entered into a strategic co-promotion partnership with Menarini Silicon Biosystems (MSB), the pioneer of…

Read More

OpGen Unyvero Hospitalized Pneumonia (HPN) Panel Rapidly Identifies Bacterial Coinfections in COVID-19 Pneumonia

19-JUN-2020 (https://www.infectiousdiseaseadvisor.com/) The Unyvero HPN panel provides comprehensive diagnostic information to clinicians in less than 5 hours, with only minutes of actual hands-on time. The Unyvero Hospitalized Pneumonia (HPN) panel (OpGen, Inc., Gaithersburg, MD) identifies bacterial coinfections in <5 hours in hospitalized patients with coronavirus disease 2019 (COVID-19) pneumonia, according to a news release on…

Read More

OpGen Subsidiary Curetis GmbH and Karolinska Institute Collaborate in Study of Bacterial Co-Infections in COVID-19 Pneumonia Patients

GAITHERSBURG, Md. and HOLZGERLINGEN, Germany, April 21, 2020 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today the start of an investigator initiated collaboration with Karolinska Institutet, Sweden, to identify bacterial co-infections in patients admitted to the…

Read More

OpGen Subsidiary Ares Genetics Demonstrates Feasibility and Potential of Next Generation Sequencing (NGS) Based Antibiotic Susceptibility Testing (AST) in Multi-Center Study

VIENNA, Austria and GAITHERSBURG, Md., April 16, 2020 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that a study on the feasibility and potential of antibiotic susceptibility testing and bacterial pathogen identification using next-generation sequencing (NGS)…

Read More